Every 10-Q that Scienture Holdings, Inc. (SCNX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SCNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCNX filings page.
Scienture Holdings, Inc. reported early commercialization progress in branded specialty pharma for the quarter ended June 30, 2026. Revenue reached $343,639 for the quarter and $399,964 for the first half of 2026, up from minimal sales in 2025, driven entirely by ARBLI™ (SCN-102) losartan oral suspension. Gross profit was $335,779 in Q2.
The company remains loss-making but its quarterly net loss narrowed to $2.8 million from $6.7 million a year earlier; first-half net loss was $6.2 million versus $9.8 million in 2025. Operating expenses were $3.0 million in Q2, including $1.2 million of research and development focused on pipeline assets SCN-102, SCN-104 and SCN-106.
At June 30, 2026, Scienture held $8.2 million in cash and equivalents plus $3.0 million in restricted cash, total assets of $87.7 million and working capital of about $6.2 million. Intangible assets tied to its four product technologies totaled $70.1 million after prior-year goodwill and IPR&D impairments. New Streeterville secured notes provided $10.6 million of net debt financing in 2026, leaving total liabilities at $23.6 million. Management acknowledges prior substantial doubt about going concern but believes current liquidity, ARBLI™ revenues, the planned launch of SCN-110 and potential capital raises support operations for at least 12 months.
Scienture Holdings, Inc. posted modest early commercialization revenue while continuing to generate sizable losses in the quarter ended March 31, 2026. Revenue rose to $56,325, driven entirely by initial sales of ARBLI™ (SCN-102), but the company recorded a net loss of $3.4 million and an operating loss of $3.5 million.
Cash and cash equivalents were $3.54 million with positive working capital of about $1.97 million, versus an accumulated deficit of $83.95 million. Intangible assets tied to the Scienture pipeline totaled roughly $70.5 million after prior impairments, with SCN-102 now amortizing over 13 years.
Management highlights substantial doubt about the company’s ability to continue as a going concern, relying on ARBLI™ commercialization, tight cost control, and access to additional capital. After quarter-end, Scienture entered into new secured Streeterville notes totaling $11.42 million, funding $8.0 million immediately and placing $3.0 million in a controlled account, secured by substantially all assets.
Scienture Holdings (SCNX) filed its Q3 2025 report, showing early commercial activity with revenues of $590,050 in the quarter (vs. $64,861 a year ago) and $600,308 for the nine months (vs. $83,560). Gross profit was $574,621 for Q3, but higher operating costs led to an operating loss of $4,361,206 and a net loss of $3,607,361. Weighted average shares were 18.96 million in Q3.
The balance sheet reflects the 2024 Scienture acquisition with $76.4 million in product technology intangibles and $21.37 million of goodwill. Cash was $355,692 at September 30, 2025, and accumulated deficit was $52,430,904. Management disclosed substantial doubt about the company’s ability to continue as a going concern without additional financing.
As part of a strategic realignment, the company sold IPS, Softell and Bonum Health on April 30, 2025 in exchange for a $5,000,000 promissory note (prime rate, balloon due June 30, 2030), recording a $385,528 loss on disposition and $62,500 of interest income. Common shares outstanding were 23,132,260 as of September 30, 2025; the company reports 40,630,815 shares outstanding on November 12, 2025.
Scienture Holdings, Inc. (f/k/a TRxADE Health) reported a weak operating quarter with minimal revenue and mounting losses while consolidating a major acquisition. Total assets were $104.3 million, driven primarily by $76.4 million of acquired product technology intangibles and $21.37 million of goodwill from the July 25, 2024 Scienture acquisition. One product, SCN-102, received regulatory approval in March 2025 and commercialization is projected to begin in 2025.
Operating results show revenues of $10,258 for the six months ended June 30, 2025 and a net loss from continuing operations of $9.78 million for the same period (quarter loss $6.72 million). Cash on hand was $15,391 at June 30, 2025 and the company discloses substantial doubt about its ability to continue as a going concern. The company completed divestitures of legacy subsidiaries for a $5.0 million promissory note and maintains convertible debentures and a derivative liability related to a $3.33 million Arena financing.